Cipher Pharmaceuticals Inc.

CPH

CA17253X1050

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 01:29:59 17/07/2024 am IST			5-day change	1st Jan Change
8.31 ^CAD	-0.60%		-0.60%	+50.00%

13/05	Cipher Pharmaceuticals Downgraded to Hold at Stifel GMP Following Share-Price Gains; Price Target Raised to C$9.50	MT
10/05	Transcript : Cipher Pharmaceuticals Inc., Q1 2024 Earnings Call, May 10, 2024

Cipher Pharmaceuticals, Inc.'s CIP-ISOTRETINOIN New Drug Submission Accepted for Review by Health Canada

January 30, 2012 at 06:30 pm IST

Cipher Pharmaceuticals, Inc. announced that its New Drug Submission for CIP-ISOTRETINOIN, a novel, patented formulation of the acne medication isotretinoin, has been accepted for review by Health Canada. The company expects a response from Health Canada in the first quarter of 2013.

Latest news about Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals Downgraded to Hold at Stifel GMP Following Share-Price Gains; Price Target Raised to C$9.50	13/05	MT
Transcript : Cipher Pharmaceuticals Inc., Q1 2024 Earnings Call, May 10, 2024	10/05
Cipher Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Transcript : Cipher Pharmaceuticals Inc., Q4 2023 Earnings Call, Mar 15, 2024	15/03
Tranche Update on Cipher Pharmaceuticals Inc.'s Equity Buyback Plan announced on November 15, 2023.	15/03	CI
Cipher Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03	CI
Cipher Pharmaceuticals Q4 Profit Falls 61% on Charges	15/03	MT
Cipher Pharmaceuticals Brief: Q4 Net income and earnings per common share were US$7.7 million and $0.32, respectively	15/03	MT
Cipher Pharmaceuticals Brief: Q4 Total revenue was US$4.9 million, consistent with Q4 2022	15/03	MT
Cipher Pharmaceuticals Upgraded to Buy at Stifel GMP; Price Target Raised to C$8.00	14/02	MT
Cipher Pharmaceuticals Brief: Announcing that its common shares are now trading on the OTCQX Best Market	29/01	MT
Cipher Pharmaceuticals Announced Normal Course Issuer Bid	16/11	MT
Cipher Pharmaceuticals Brief: Announcing Normal Course Issuer Bid	16/11	MT
Cipher Pharmaceuticals Inc. announces an Equity Buyback for 1,337,195 shares, representing 5.57% of its issued share capital.	16/11	CI
Cipher Pharmaceuticals Inc. authorizes a Buyback Plan.	15/11	CI
Cipher Pharmaceuticals Seeks Acquisitions	10/11	CI
Transcript : Cipher Pharmaceuticals Inc., Q3 2023 Earnings Call, Nov 10, 2023	10/11
Tranche Update on Cipher Pharmaceuticals Inc.'s Equity Buyback Plan announced on September 19, 2022.	10/11	CI
Cipher Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Cipher Pharmaceuticals Announced Final Results of Substantial Issuer Bid	12/23/12	MT
Tranche Update on Cipher Pharmaceuticals Inc.'s Equity Buyback Plan announced on September 5, 2023.	12/23/12	CI
Cipher Pharmaceuticals Inc.'s Equity Buyback announced on September 5, 2023, has closed with 1,290,321 shares, representing 5.1% for CAD 6 million.	11/23/11	CI
Cipher Pharmaceuticals Inc.'s Equity Buyback announced on September 19, 2022, has expired with 284,843 shares, representing 1.13% for CAD 1.03 million.	21/23/21	CI
Cipher Pharmaceuticals Plans Substantial Issuer Bid	05/23/05	MT
Cipher Pharmaceuticals Inc. announces an Equity Buyback for CAD 6 million worth of its shares.	05/23/05	CI

Chart Cipher Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Cipher Pharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.31 CAD

Average target price

10.67 CAD

Spread / Average Target

+28.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CIPHER PHARMACEUTICALS INC.	+50.00%	15Cr
ELI LILLY AND COMPANY	+61.53%	86TCr
NOVO NORDISK A/S	+38.95%	63TCr
JOHNSON & JOHNSON	-3.66%	36TCr
MERCK & CO., INC.	+15.06%	32TCr
ABBVIE INC.	+9.18%	30TCr
ROCHE HOLDING AG	+5.89%	23TCr
NOVARTIS AG	+16.53%	23TCr
AMGEN INC.	+15.67%	18TCr
PFIZER, INC.	+2.47%	16TCr

Other Pharmaceuticals